The Lancet 柳叶刀· Megan E Daly, Charles B Simone, Mary W Redman, Ming-Hui Hsieh, Paul J Hesketh, Chen Hu, Arta M Monjazeb, Conor E Steuer, Apar K Ganti, Rojano Kashani, Jessica R Bauman, Josephine L Feliciano, James Moon, Kimberly Ku, Nguyet Le-Lindqwister, Andrew M Baschnagel, Sanjay Maraboyina, Garrett B Sherwood, Daniel Almquist, Kristin A Higgins, Jhanelle E Gray, Jeffrey D Bradley, Karen Kelly·· 2026-09-07精选AI 评分85
SWOG/NRG S1914 III 期 RCT 显示阿替利珠单抗联合 SBRT 未改善高危早期非小细胞肺癌总生存且增加高级别不良事件
[Articles] Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914): a multicentre, open-label, superiority, phase 3, randomised controlled trial
AI 导读
在不可手术高危早期非小细胞肺癌的SWOG/NRG S1914多中心、开放标签、优效性III期随机对照试验中,阿替利珠单抗诱导加巩固联合立体定向体部放疗(SBRT)较单纯SBRT未改善总生存,且联合组3级及以上不良事件更多,该研究为首个在此人群中评估免疫治疗的完整报告III期协作组试验。
推荐理由
在可手术高危早期非小细胞肺癌的多中心三期试验中,阿替利珠单抗联合SBRT未提高总生存率且3级及以上不良事件增加,该阴性结果直接改变此类患者治疗路径。
来源:The Lancet 柳叶刀 · thelancet.com